HIV Gene Therapy

Engineered Red Blood Cells Act as Decoys for HIV

Published in AIDS Weekly, October 30th, 2000

Genetically engineering red blood cells to express the CD4 receptor may be a way to "fool" HIV in vivo, researchers in Australia suggest.

"Early stages of HIV infection are associated with an acute phase of viremia followed by a chronic, clinically latent period that may last as long as 10 years," stated R.F. Minchin and A.S. Cronin, University of Western Australia. "Decreasing total body viral burden during these early phases of infection may not only prolong the chronic latent period but also decrease the likelihood for viral transmission."

Minchin and Cronin presented data from their study at the conference Gene, Drug Therapy, and Molecular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-10-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry